Trial · NCT01804400
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Total Nasal Symptom Score from baseline at 14 days | Baseline, Day 14 | Total Nasal Symptom Score (TNSS) averaged over the last two hours (2-4h) of exposure following 14 days treatment with QAW039 and/or Montelukast or matched placebo |
| Secondary | Change in Total Ocular Symptom score from Baseline at 14 days | Baseline, Day 14 | Total Ocular Symptom Score (TOSS), defined as the sum of ocular symptoms of eye tearing, itching, watery eyes and redness, each of which is scored on a scale from 0 and 3 |
| Secondary | Change in Nasal Flow from baseline at 14 days | Prior to, and every 60 min during allergen exposure period | Measured using rhinomanometry Flow rates at 150 Pa will be obtained separately for the right and left nostrils (cm\^3/second). The sum of the flow rates of both nostrils will be calculated from the two measurements |
| Secondary | Change in Nasal excretion weight from baseline at 14 days | Baseline, Day 14 | Total weight of tissues (before and after use) |
| Secondary | Change in Forced Expiratory Volume in 1 Second (FEV1) from baseline at 14 days | Baseline, Day 14 | Change in FEV1 from Baseline |
| Secondary | Change in Forced Vital Capacity (FVC) from baseline at 14 days | Baseline, Day 14 | Change in FVC from Baseline |
| Secondary | Change in FEV1/FVC at from baseline at 14 days | Baseline, Day 14 | Change in FEV1/FVC from Baseline |
| Secondary | Plasma Concentration maximum (Cmax) | Day 1-14 | Determined at steady state in plasma |
| Secondary | Plasma Concentration Minimum (Cmin) | Day 1-14 | Determined at steady state in plasma |
| Secondary | Plasma Concentration Average (Cav) | Day 1-14 | Determined at steady state in plasma |
| Secondary | Time of Cmax (Tmax) | Day 1-14 | Determined at steady state in plasma |
| Secondary | Area Under Curve (AUCtau) | Day 1-14 | Determined at steady state in plasma |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01804400/registered